Be aware of hidden #KLM hidden charges. NO FARE FOR BOOKING CODE. KLM will downgrade a booking class when you want to make a change and then requesting a 1000€ fee to upgrade for another class, while original class is avaible. This is despicable business practice KLM.!!
Huge thanks to co-chairs; DG @NCDCgov@DGatNAFDAC for the opportunity to present CEPI’s Lassa vaccine research & development efforts to Nigeria’s Lassa Vaccine Task Team
Continuing efforts to strengthen our partnerships in the country & region
@breugeltweeting@katrin_ram
The reach of #RiftValley fever is expanding, yet no vaccines are currently approved for human use. We’re looking to change that ⬇️💉
Learn more on our website: https://t.co/WJ0v8u4lRB
#Lassa fever has plagued parts of West Africa for >50 years – with no vaccine to defend against it. But CEPI is making strides to change this, laying the foundations for the 1st-ever Phase 3 Lassa vaccine efficacy trial in West Africa 🔬👩🏿🔬
Find out how ⬇️https://t.co/TyTktH02mG
There is still a lot of work to do on #pandemicpreparedness, and at the #WHOPandemicHub, we are working on the most important recommendations for "fit-for-purpose surveillance systems".
We need to create a ‘library’ of vaccine candidates that are ready to be pulled off the shelf and swiftly adapted next time Disease X emerges. That way, we don’t lose valuable time creating a new vaccine from scratch. #100DaysMission https://t.co/ZIf695vJAX
Instead of working to make vaccines against each unique coronavirus or variant, what if we could provide broad protection across the field through an all-in-one coronavirus shot? 🔬 🌍 https://t.co/kgKzLv8ySJ
This week, we had the pleasure of co-hosting a workshop in Abuja 🇳🇬, with @NCDC. Scientists gathered from across West Africa to review progress of their ongoing #LassaFever research as part of the Enable study—the largest ever Lassa fever study 🧵(1/10)
Delighted to see @WHO convene a meeting with @CEPIvaccines@NCDCgov@AfricaCDC in Abuja, to deliberate the options we have as a global community to accelerate the development & licensure of #Lassafever vaccines
Proud of the role of West African institutions in driving this work
Today, at the #Enable#Lassa Research Programme mid-term workshop, bringing together #LassaFever experts from Liberia, Sierra Leone, Guinea, Benin Republic, and Nigeria.
Discussions started with a plenary session on 'site readiness for clinical trials'
#TodayInNCDC
Teaming with @CEPIvaccines, we're hosting #LassaFever experts from Nigeria, Benin, Guinea, Liberia, & Sierra Leone to review the progress of the #Enable study
#Enable aims to provide a detailed description of #LF epidemiology in West Africa
https://t.co/QlFvagGDFZ
Great exchange of ideas and experiences during the Enable Lassa Fever workshop in Abuja, Nigeria, organized by @CEPIvaccines Very proud to be leading this!
Today at #WHS2022, @starkwatzinger, Federal Minister of Education & Eesearch (@BMBF_Bund) announced a further €100M in funding to support CEPI's R&D focussed plan to end pandemic.
https://t.co/uYn8lX4HVi
#The100DaysMission envisages a future where vaccines against a new infectious threat can be developed in just 100 days.
Join CEPI at #WHS2022 where we will explore how the world can achieve this critical mission https://t.co/B8IuRpu9l7
👀See who'll be joining our panel 👇
Thanks to all partners and participants in all five countries to make this happen. We could not have done it without your tiresless efforts and support.
Did you know❓ Our study, Enable, is the largest ever research programme to provide a more accurate assessment of Lassa fever infections in West Africa.
The study is running across Benin 🇧🇯, Liberia 🇱🇷, Guinea 🇬🇳, Nigeria 🇳🇬 and Sierra Leone 🇸🇱: https://t.co/I61gtRdFEj